newsfilter.io
Aug 10, 2026, 7:19 AM ETHealthcare

Apogee Therapeutics — Second Quarter 2026 Earnings Summary

APGEAPOGEE THERAPEUTICS INC
Source

Financial Performance

  • Cash, cash equivalents, marketable securities, and long-term marketable securities totaled $1.3 billion as of June 30, 2026, compared to $621.2 million as of June 30, 2025.
  • Research and development (R&D) expenses were $67.3 million for the quarter ended June 30, 2026, an increase from $55.7 million in the same period of 2025.
  • General and administrative (G&A) expenses were $24.3 million for the quarter ended June 30, 2026, up from $17.5 million in the quarter ended June 30, 2025.
  • Net loss was $85.9 million for the quarter ended June 30, 2026, compared to a net loss of $66.1 million for the quarter ended June 30, 2025.
  • Total operating expenses for the quarter were $96.0 million, including $4.4 million in merger transaction costs, compared to $73.2 million in the prior year quarter.
  • Interest income, net was $11.8 million for the quarter ended June 30, 2026, compared to $7.1 million in the prior year quarter.
  • Interest expense was $1.6 million for the quarter ended June 30, 2026, compared to $0 in the prior year quarter.
  • Total assets were $1.34 billion as of June 30, 2026, compared to $937.1 million as of December 31, 2025.
  • Total liabilities were $141.2 million as of June 30, 2026, compared to $33.3 million as of December 31, 2025, driven by a $99.2 million revenue share liability.

Guidance and Future Outlook

  • The company plans to advance zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis in 2026.
  • The ELEVATE Phase 2a trial for eosinophilic esophagitis (EoE) is expected to initiate in the second half of 2026.
  • The ASPIRE Phase 2b trial for asthma is expected to initiate in the first half of 2027.
  • Interim data from the Phase 1b head-to-head study of APG279 (zumilokibart + APG990) is expected in the second half of 2026.
  • Additional plans for the APG273 program are expected to be announced in the second half of 2026.
  • The proposed acquisition by AbbVie is expected to close in the third quarter of 2026, subject to customary closing conditions.

Business Segments and Product Lines

  • Zumilokibart (APG777): Positive 16-week induction dose optimization results from the APEX Phase 2 Part B trial met all primary and secondary endpoints. 65.9% of patients treated with the mid-dose achieved EASI-75 (41.9% placebo adjusted). Secondary endpoints included IGA 0/1 (46.0%), EASI-90 (47.4%), I-NRS ≥4 improvement (50.5%), EASI-100 (16.5%), and very low disease activity (20.6%).
  • APG279: A Phase 1b head-to-head study evaluating the combination of zumilokibart and APG990 versus DUPIXENT® in atopic dermatitis is ongoing.
  • APG273: A long-acting IL-13/TSLP combination program continues to advance following positive Phase 1 data for APG333.
  • Pipeline Expansion: The company is advancing trials for EoE and asthma indications for zumilokibart.

Market and Competitive Landscape

  • Apogee is targeting the largest inflammatory and immunology (I&I) markets, including atopic dermatitis (AD), asthma, EoE, and COPD.
  • The company positions its portfolio to offer best-in-class profiles with optimized dosing compared to existing therapies.
  • The proposed acquisition by AbbVie aims to strengthen AbbVie's immunology portfolio and leverage AbbVie's global scale and commercial capabilities.

Risks and Challenges

  • The proposed acquisition may not close in the anticipated timeframe or at all due to failure to satisfy closing conditions, including regulatory or shareholder approval.
  • Risks include the possibility of competing acquisition proposals, unexpected costs or charges related to the acquisition, and potential disruption to business operations.
  • Pipeline assets, including zumilokibart, may not demonstrate anticipated success, safety, or efficacy in future clinical trials.
  • Risks related to litigation, regulatory actions, intellectual property challenges, and adverse market or economic conditions are noted.

Management Commentary and Tone

  • CEO Michael Henderson, M.D., described the second quarter as a "transformational period" for Apogee.
  • Management highlighted that Phase 2 results reinforced the potential of zumilokibart to redefine treatment for moderate-to-severe atopic dermatitis.
  • The company expressed gratitude to patients, investigators, and employees, and stated that AbbVie's expertise provides the best opportunity to realize the full potential of the programs.
  • The tone reflects confidence in the pipeline's progress and the strategic value of the pending acquisition.

Analyst Questions and Answers

  • No analyst questions and answers section was included in the press release.

Other Key Points

  • Acquisition Terms: AbbVie agreed to acquire all outstanding shares of Apogee for $135.11 per share in cash, representing a total equity value of approximately $10.9 billion.
  • Strategic Financing: In May 2026, Apogee announced a collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital to support Phase 3 development and commercialization of zumilokibart.
  • Share Count: As of June 30, 2026, there were 75,611,894 shares issued and 75,339,499 shares outstanding.
  • Revenue Share Liability: A new revenue share liability of $99.2 million was recorded on the balance sheet as of June 30, 2026.